乙型肝炎病毒母婴“零传播”策略分析

新发传染病电子杂志 ›› 2020, Vol. 5 ›› Issue (1): 25-27.

乙型肝炎病毒母婴“零传播”策略分析

杨立新¹, 白淑芬², 和沁园³, 马常兰⁴

1.南京中医药大学附属南京医院、南京市第二医院超声科,南京 210003;
2.南京市浦口区中医院妇产科,南京 211800;
3.南京中医药大学附属南京医院、南京市第二医院妇产科,南京 210003;
4.江苏卫生健康职业学院,南京 211800

出版日期:2020-01-20 发布日期:2020-04-22
通讯作者: 马常兰,Email:mcl9966@163.com
基金资助:
南京市浦口区科技发展社会事业项目（S2017-06）

Strategy analysis of eliminate mother-to-child hepatitis B virus transmission

Yang Lixin¹, Bai Shufen², He Qinyuan¹, Ma Changlan³

1.Department of Ultrasound, Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, The Second Hospital of Nanjing, Nanjing 210003, China;
2.Department of Gynecology and Obstetrics, Nanjing Pukou District Hospital of Traditional Chinese Medicine, Nanjing 211800, China;
3.Department of Gynecology and Obstetrics, Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, The Second Hospital of Nanjing, Nanjing 210003, China;
4.Jiangsu Health Vocational College, Nanjing 211800, China

Online:2020-01-20 Published:2020-04-22

摘要/Abstract

摘要： 目的探讨实现乙型肝炎病毒(HBV)母婴“零传播”的可行性策略。方法回顾性分析2005年1月至2015年12月南京市第二医院进行HBV母婴阻断治疗病例,总结母婴传播的高危因素,采取的有效阻断措施和阻断结果等。结果 HBV感染孕妇不论是乙型肝炎表面抗原(+)[HBsAg(+)]、乙型肝炎表e抗原(+)[HBeAg(+)]、乙型肝炎核心抗体(+)[HBcAb(+)]还是HBsAg(+)、乙型肝炎e抗体(+)[HBeAb(+)]、HBcAb(+),只要乙型肝炎病毒脱氧核糖核酸（HBV DNA）<1.0×10⁶拷贝/ml,均未发现乙型肝炎母婴传播的病例;HBV DNA≥1.0×10⁶拷贝/ml的孕妇,自孕28周左右口服核苷类似物替比夫定或替诺福韦行抗病毒阻断治疗者,亦未发现乙型肝炎母婴传播的病例;HBV母婴传播仅发生在HBV DNA>1.0×10⁶拷贝/ml且孕期未进行抗病毒阻断的病例;HBV感染孕妇的婴儿进行乙型肝炎疫苗及乙型肝炎免疫球蛋白（HBIG）联合免疫后,在2月龄、7月龄、12月龄检查乙型肝炎病毒表面抗体,若<100U/ml,给予加强补种一针乙型肝炎疫苗,可达到有效的乙型肝炎疫苗免疫效果。结论 HBV DNA载量是乙型肝炎母婴传播的关键预测指标;对于HBV DNA高载量孕妇进行核苷类似物抗病毒治疗有效;正规及时的联合免疫,以及对乙型肝炎疫苗低应答婴儿加强疫苗接种阻断母婴传播;上述3项措施联合进行可以实现HBV母婴“零传播”。

关键词: 乙型肝炎病毒, 宫内感染, 零传播, 婴儿, 新生儿

Abstract: Objective To elaborate on the feasibility strategy for achieving "zero mother-to-child transmission (MTCT) of HBV". Methods This retrospective study was performed in the Second Affiliated Hospital of Southeast University from January 2005 to December 2015 to evaluate the effects of the strategy of eliminating mother-to-child HBV transmission and to summarize the high-risk factors of mother-to-child transmission. Result No cases of mother-to-child HBV transmission were found if hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) positive mothers with HBV DNA, have HBV DNA was less than 1.0×10⁶copies/ml. If mothers with HBV DNA levels above 1.0×10⁸copies/ml managed with oral use of telbivudine or tenofovir to implement antiviral therapy from 28 weeks of gestation, there are also no cases of mother-to-child HBV transmission were found. HBV mother-to-child transmission occurred only in HBV DNA>1.0×10⁶copies/ml and case of not implementing antiviral therapy during pregnancy. After a birth dose of hepatitis B immunoglobulin (HBIG), in combination with hepatitis B vaccine (HepB), was used for infants born to HBV infected mothers and check the hepatitis B surface antibody (HBsAb) for infants at 2 months, 7 months and 12 months, a replenish of HepB was given to strengthen the vaccine if infants with HBsAb titer was less than 100. Conclusion HBV DNA load is a key predictor of mother-to-child HBV transmission. Antiviral treatment of nucleoside analogs in pregnant women with high HBV DNA load can be effective. The combination of immunization and enhanced follow-up for infants with a low response to HepB, and strengthen vaccination if necessary to block mother-to-child transmission, can achieve “zero mother-to-child HBV transmission”.

Key words: Hepatitis B virus, Intrauterine infection, Zero transmission, Infant, Neonatal

杨立新, 白淑芬, 和沁园, 马常兰. 乙型肝炎病毒母婴“零传播”策略分析[J]. 新发传染病电子杂志, 2020, 5(1): 25-27.

Yang Lixin, Bai Shufen, He Qinyuan, Ma Changlan. Strategy analysis of eliminate mother-to-child hepatitis B virus transmission[J]. Electronic Journal of Emerging Infectious Diseases, 2020, 5(1): 25-27.

[1]	易永祥. 乙型肝炎病毒的分子流行病学研究进展[J]. 新发传染病电子杂志, 2020, 5(1): 1-7.
[2]	韦小兰, 骆子义, 邬宇美, 车芳, 刘雪梅, 刘凡. 利用多重实时荧光定量PCR技术检测新生儿高胆红素血症患者UGT1A1基因多态性研究[J]. 新发传染病电子杂志, 2017, 2(1): 18-21.